Skip to main content
ANAB $46.63 -1.62%
ANAB logo
ANAB · Anaptysbio, Inc
Track ANAB — free
$46.63 -0.77 (-1.62%) At close · Nov 20
Market Cap
$1.39B
Shares
29.90M
Volume · Nov 20 432.48K Avg daily vol (3M) 494.29K
All webcasts

Earnings call · FY2027 Q1

Anaptysbio, Inc (ANAB) Q1 2027 Earnings Call

Concluded Nov 12, 2026
Nov 12, 2026
Period
FY2027 Q1
Runtime
—
Sources
2 artifacts
Revenue $30.27M +18.5% YoY
Diluted EPS $0.11
Net income $3.88M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 12, 2026
AnaptysBio reported Jemperli global net sales of $1.0 billion (£753 million) through September 30, 2026, up 29% year-over-year, and U.S. approval in stage II and III MSI-H/dMMR locally advanced rectal cancer. A GSK and Tesaro judgment is anticipated in calendar Q4 2026 or Q1 2027.
10-Q report · filed Nov 12, 2026
AnaptysBio reported $30.3 million in collaboration revenue for the three months ended September 30, 2026, down from $76.3 million, while Jemperli received accelerated FDA approval for previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer.

The audio replay and transcript follow the call.

Forward guidance

2 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Nov 12, 2026.

Metric Guided
Annualized Jemperli royalties payable to Anaptys
as early as 2029
at least $390M
Paydown
calendar H2 2027
$270M
Full-screen source Call document